Benjamin Lyons

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

David S Mendelson, M. Morris, H. Scher, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Molly Brewer, Beth Y Karlan, Daniela Matei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.